phase i study of ly3410738: a first-in-class idh1-r132 inhibitor
Published 3 years ago • 284 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:52
results of phase i study of mcl-1 inhibition with azd5991 in r/r hematologic malignancies
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:37
long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
-
1:48
idh1 inhibitor ivosidenib for the treatment of relapsed/ refractory aml
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:20
einleitung (1/14)
-
21:38
drawing the line: the rationale behind blood tube collection order
-
31:17
blood health - dr lim zi yi | centre for clinical haematology
-
7:47
first aid measures in the histopathological section
-
3:52
a phase ii study evaluating the safety and efficacy of olutasidenib in patients with r/r midh1 aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
2:41
a phase i/ii study of afm13 in combination with cord blood-derived nk cells in patients with r/r hl
-
2:47
blood
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
1:04
a phase i/ii study evaluating ms-553 in patients with cll/sll
-
3:10
results of phase ii trial of olutasidenib in patients with r/r midh1 aml
-
4:09
nei-labtv profile: jennifer kielczewski, laboratory of immunology
-
6:11
i-box - central line blood sampling